A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.

Trial Profile

A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Cisplatin (Primary) ; GC 4419 (Primary)
  • Indications Head and neck cancer; Mucositis
  • Focus Adverse reactions
  • Sponsors Galera Therapeutics
  • Most Recent Events

    • 27 Sep 2016 Results (n=46) published in the Galera Therapeutics Media Release
    • 27 Sep 2016 According to a Galera Therapeutics media release, final data including one-year tumor control from this trial (n=46) presented at the American Society of Radiation Oncology (ASTRO) Annual Meeting.
    • 21 Sep 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top